News
April 24, 2006
OSU researchers have cracked the site and the stages of development for the last major set of human immune cells. The researchers, led by Michael Caligiuri, MD, director, OSU Comprehensive Cancer Center, found that natural killer (NK) cells -- one of the body's front-line defenses against cancer and infections -- mature from progenitor stem cells in four discrete stages.
The rest of the story
|
|
April 18, 2006
Research at OSU shows that a protein made by a cancer-causing virus that was thought to be unimportant for its replication is in fact critically needed by the virus to initiate an infection and to reproduce. The study examined the human T lymphotropic virus type 1 (HTLV-1), which has been linked to adult T-cell leukemia and lymphoma, and a protein it makes called p13.
The rest of the story
|
|
April 11, 2006
-- New research led by scientists with the OSU Cancer Program and OSU College of Veterinary Medicine shows that a protein made by a cancer-causing virus that was thought to be unimportant for its replication is in fact critically needed by the virus to initiate an infection and to reproduce.
The study examined the human T lymphotropic virus type 1 (HTLV-1) and a protein it makes called p13. The protein is one of the virus' so- called accessory proteins, proteins that earlier studies done in laboratory-grown cells suggested that the virus could live without.
It is important to understand the function of these accessory molecules to determine if they should be incorporated into vaccines or targeted by new drugs as a way to prevent infection, said principal investigator Michael Lairmore, professor and chair of veterinary biosciences and a member of the OSU Comprehensive Cancer Center.
-- > SEE: http://researchnews.osu.edu/archive/mitoprot.htm
The rest of the story
|
|
April 11, 2006
-- Clay Marsh, MD, has been appointed director of OSU Medical Center's new Center for Critical Care and Respiratory Medicine. Marsh is currently division director of Pulmonary, Critical Care and Sleep Medicine at OSU and associate director for lung research at the Davis Heart and Lung Research Institute. He is the first staff member for the Center for Critical Care and Respiratory Medicine, which has been in development for the last year. The center will focus on providing innovative solutions for patients undergoing critical care and those with lung disease. Critical Care is one of the Medical Center's six Signature Programs and is expected to have a national impact on OSUMC's advancement of personalized health care. Read more at http://medicalcenter.osu.edu/mediaroom/press/article.cfm?ID=2555.
The rest of the story
|
|
March 28, 2006
Faculty, staff and students are invited to learn about new research being conducted by OSU research trainees at the fifth annual Graduate and Post Graduate Research Day on Thursday (3/30) on the first floor of Meiling and Graves halls. More than 200 projects will be displayed in a day-long event that will also feature guest lectures by biomedical researchers from Northeastern University and Duke University Medical Center scientists, as well as the president of the New York Academy of Sciences.
-- > SEE: http://medicine.osu.edu/researchday
The rest of the story
|
|
March 20, 2006
Scientists at OSU have discovered a previously unknown mechanism that cells use to fight off the human immunodeficiency virus (HIV), the cause of AIDS.
The rest of the story
|
|
March 16, 2006
March 24th is World TB day.
http://www.stoptb.org/events/world_tb_day/2006/
The rest of the story
|
|
January 19, 2006
-- A new study suggests that antibody-based cancer drugs might help patients more if they are given with substances that stimulate the immune system.
The study is the first to indicate that the drug trastuzumab, also known as Herceptin, may work better when it is followed by injections of interleukin (IL) 2 or IL-12. Both substances trigger the activity of immune cells known as natural killer (NK) cells.
The research, by scientists at Ohio State's Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, is published in the Jan. 1 issue of the journal Cancer Research.
-- > SEE: http://researchnews.osu.edu/archive/nkchemokines.htm
The rest of the story
|
|
January 03, 2006
INFECTIOUS AGENT THWARTS DEFENSE MECHANISMS
-- A new study found that an extremely infectious pneumonia-like disease in humans slips through the immune system's usual defense mechanisms.
The bacterium at fault, Francisella tularensis, causes the disease tularemia. Also known as rabbit fever, tularemia is fatal in less than 1 percent of treated cases and in about 5 percent of untreated cases. It is a rare disease with only about 300 cases per year occurring in the United States. But the disease can make many people very ill very fast, said Mark Wewers, the study's lead author and an assistant director of the Davis Heart and Lung Research Institute at Ohio State.
-- > SEE: http://researchnews.osu.edu/archive/tulabug.htm
The rest of the story
|
|
December 12, 2005
Dr. Kurt Stevenson of infectious diseases offers tips on how to avoid any type of flu.
The rest of the story
|
|
Previous
Next
|
